MXRA8 levels are associated with cancer immunity, and ICI is changing the treatment paradigm for many cancers (43), with adequate infiltration of tumor-reactive CD8+ T cells a prerequisite for the ICI response (44). This evidence concerns the gene CD8A and neoplasm.